| Document Date: 2008-09-18 21:30:47
Open Document File Size: 21,76 KBShare Result on Facebook
City Tokyo / Tarrytown / / Company Regeneron Pharmaceuticals Inc. / Astellas Pharma Inc. / Regeneron Research Laboratories / / Country Japan / / Currency USD / / Event FDA Phase / Business Partnership / / IndustryTerm biopharmaceutical / treatment of cancer / pharmaceutical market / technology platforms / pharmaceutical / pharmaceutical products / antibody products / / MedicalCondition particular disease / cancer / diseases / inflammatory diseases / eye diseases / disorders / / Person George D. Yancopoulos / Masafumi Nogimori / Toshinari Tamura / / Position Chief Scientific Officer / President / President & CEO / Executive Vice President and Chief Scientific Officer / / Product VelocImmune / VelocImmune platform / VelocImmune® / / Technology ANTIBODIES / VelocImmune technology / / URL www.regeneron.com / http /
SocialTag |
ASTELLAS LICENSES REGENERON’S VELOCIMMUNE® TECHNOLOGY FOR DISCOVERING HUMAN MONOCLONAL ANTIBODIES Tokyo, Japan and Tarrytown, NY – (March 30, 2007) – Astellas Pharma Inc. (“Astellas”; Headquarters: Tokyo, Japa